

Using information to improve quality & choice

What is the NCIN?

Dr Mick Peake
Clinical Lead, NCIN
www.ncin.org.uk





Using information to improve quality & choice

Goal for NCIN: "To develop the best cancer information service of any large country in the world – by 2012"

Mike Richards 2007

www.ncin.org.uk



NCIN Partners













National

Services

Scotland




























Cancer Registry











NTELLIGENCE UNIT

Cancer Screening Programmes

NCIN Direct Funders


















NCIN Governance





NCIN Governance



Public Health England

NCRI Board

Ch. Ken Calman

Health Departments

e.g. DH Cancer Programme Board

NCIN Steering Group

Ch. Alex Markham

Clinical
Outcomes Group
Co-ch: Mike Richards
& Mick Peake

SSCRG Chairs Forum

Ch: Mick Peake

Scientific Advisory
Group

Ch: Henrik Moller



NCIN Organisation



NCIN Co-ordinating Senior Team

Chris Carrigan; Di Riley; Mick Peake; Henrik Möller; Anna Gavin; Michael Chapman

NCIN Central Team (~ 20)

Other partners (e.g. LSHTM)

UK Association of Cancer Registries

8 English Cancer Registries



NCIN core objectives



- Promoting efficient and effective data collection throughout the cancer journey
- Providing a common national repository for cancer datasets
- Producing expert analyses, based on robust methodologies, to monitor patterns of cancer care
- Exploiting information to drive improvements in standards of cancer care and clinical outcomes
- Enabling use of cancer information to support audit and research programmes



Site-Specific Clinical Reference Groups



- Brain/CNS
- Breast
- Children, Teenage & Young Adults
- Colo-rectal
- Gynaecological cancers
- Haematological cancers (including lymphoma)
- Head & Neck (including thyroid)
- Lung (including mesothelioma)
- Bone & soft tissue Sarcoma
- Skin (including non-melanoma)
- Upper GI (including Hepato-biliary)
- Urology (all 4 sub-types)



Site-Specific Clinical Reference Groups



- In place since late 2008
- Very varied 'starting points' (e.g. Lung vs CNS tumours)
- Multi-disciplinary membership
- Strong links with professional bodies
- Work closely with a lead Cancer Registry
- Chairs' Forum meets twice a year
- Each holds annual workshops with Network SSG chairs
- Examples of work to date:
 - National Cancer Dataset
 - Review of National Cancer Data Repository
 - Work programmes
 - Production of 'data briefings'
 - Supporting Peer Review (Clinical Lines of Enquiry)



'Cross-cutting' Groups



- Radiotherapy
 - collection and use of RT data
- Chemotherapy
 - development and implementation of dataset
- Pathology (with RCPath)
 - datasets
- Radiology: Joint RCR/NCIN working party
 - proforma-based (codable) reporting (diagnosis/stage)
 - extraction of data from RIS systems
- Co-morbidity
- National Cancer Staging Panel (workshop 10th June)
- Health Economics workstream being established (workshop October 28th)



NCIN – Main outputs



- National Cancer Data Repository
- National level reports
- E-Products:
 - eAtlas
 - Cancer Commissioning Toolkit
 - GP Practice profiles
- Data briefings
- Dataset development & implementation:
- Clinically-led work programmes
- HES-based 'microsites' (with NatCanStat)



Who do we produce intelligence for?



- Clinicians
- Department(s) of Health
- Health Care Providers
- Health Care Commissioners
- Research Community
- National Statistics
- International Cancer Benchmarking Partnership
- Patients and the public



National Cancer Data Repository (v2008)



Registry-HES linkage: 1985-2008 (England)

- >7.3 million tumour records from Registries
 - c. 30 fields of data
- >49 million hospital in patient episodes
 - c. 150 fields of data

Recently added

- National Cancer Audit data
- Co-morbidity (Charslon Index) recently added
- Radiotherapy Dataset now ready for analyses



National Cancer Data Repository: Potential linkages



- National cancer screening databases
- Outpatient HES
- IMS/ electronic chemotherapy prescribing (sample)
- National Cancer Dataset from Multi-disciplinary teams (stage, co-morbidity, performance status, etc.)
- Radiology reports & PET scans (2011?)
- Clinical trials
- Genetic/biobank and other research datasets
- PCT cancer budgeting data
- Scotland, Wales, Northern Ireland



Some national reports & analyses - www.ncin.org.uk



- UK incidence & mortality
- One year survival
- Deprivation
- Prevalence
- Ethnicity
- Male Cancers
- Major Surgery
- Routes to Diagnosis
- Cervical, Breast and Head & neck cancers
- 30-day mortality after coo-rectal surgery



NCIN: Incidence and mortality



New cancer cases, crude and age-standardised* incidence rates per 100,000 (with 95% confidence intervals), Cancer Networks, UK, 2005




C15: Oesophagus

Trends in one year cancer survival, England, 1985-2004



		Males	;		Fe	male	s		Pe	rsons	i
Consor Welmork	Number of C	rade Add	SSM confidence	Mandar of	Crade	ARR	BSM combines brismal	Mandar of	Crade	ARR	SIN confiden
Of Lengerhin and South Cumbris OH		W15 601		4.157	504.2	201.0	346.4 - 387.5	8.57%	533.1	400.0	202.1 - 400
(II) Smaller Manufactor and Cheditin CN		2004 4800	640.4 - 680.8	T,120	482.8	MI.2	548.5 - 380.0	14,815	480.1	4012	207.2 - 610
GI Meneralite and Chestine Ch		H10 6414	611.0 - 655.8	5.206	525.2	307.2	278.2 - 388.4	10,206	522.0	415.4	407.0 - 423
Of Yorkship CH	-	203 4072	608.T - 627.9	0.005	405.0	2015	345.2 - 384.0	12,121	487.1	200.0	278.0 - 200
NOT Humber and Yorkshine Creat CH		201 4002	285.0 - 615.7	2,650	502.5	201	242.4 - 371.4	5.118	514.3	271.5	200.0 - 202
COS North Treed CN		017 ATC		4.000	519.6	276.2	206.8 - 207.7	9.285	527.8	4014	205.0 - 612
KT1 Fan Birmingham CN		94.0 434.1	621.2 - 661.9	4.201	423.0	201.4	345.1 - 387.8	2.000	461.0	395.2	288.T - 403
KIZANIN CH		821 2044	-2-2	2,218	665.7	200.0	221.2 - 350.7	4,517	458.8	200.2	249.3 - 271
TO MICTING ON		W12 4784		4.076	411.0	200.1	347.4 - 320.9	8,279	530.1	201.0	389.2 - 301
Int Describing ON		NT 8 428.4	605.4 - 645.4	1,645	470.4	201.0	232.0 - 389.0	3,407	488.8	388.2	276.T - 601
CIT Lates Notherts and Refred CH		814 4825	2024 - 410.8	3,620	663.5	202.2	343.2 - 384.2	7.200	450.3	277.0	209.0 - 200
CO Mount Yearson CH		017 2770	362.5 - 362.6	2,824	437.0	200.1	219.4 - 240.9	4.000	429.3	201.2	245.2 - 265
C1 Wed Looks CN		H21 272.6	263.2 - 265.6	3.228	250.6	201.5	218.9 - 340.4	0.256	340.4	2010	242.2 - 202
CONNET Landon CN		W28 2005	203.7 - 403.4	2.019	223.7	mr.	292.9 - 321.0	4.039	333.0	245.8	215.8 - 217
(23 North Red London CN		252 3843		2,491	323.0	2017	289.2 - 314.2	4,800	334.1	2010	222.4 - 242
Of South East London CN	2,807 3	PER 4000	288.3 - 418.6	2,891	277.0	340.4	229.3 - 305.6	5,698	376.3	273.0	382.0 - 381
Q1 Sw/h Well London CN	2,882 1	907 4149	208.0 - 421.3	2,485	366.3	200.0	218.8 - 340.4	4,897	378.3	272.8	282.0 - 286
Of Periods CN	4,276 6	WT3 4724	603.4 - 638.5	5,018	802.2	382.1	279.5 - 388.7	9,790	004.7	307.3	288.0 - 405
GT Durast CN	2,401 1	202 4502	4110 - 4000	2,394	830.1	361.2	208.5 - 404.0	4.705	621.2	618.8	405.0 - 401
Cli. Avon. Summed and Williams Chi.		N24 4344	6224 - 661.0	5,010	512.9	200.0	209.5 - 282.1	10.016	542.6	607.7	229.4 - 415
201 Courties Cit	2,893 5	21.1 281.0	278.0 - 400.7	2.656	501.2	242.0	229.5 - 357.5	5.348	517.0	MILE	257.3 - 271
GO Traines Valles CN	4.817 4	27.0 400.4	289.1 - 611.6	5,083	405.4	202.0	252.5 - 373.3	9.889	401.2	201.0	27KO - 281
G1 Centel South Cost OV	6,347 6	508 428.6	411.7 - 485.0	5,812	535.2	276.9	385.0 - 386.E	10,059	542.8	300.0	201.6 - ACE
G2 Surrey, West Sussex and Hampshire CH	3,000 4	24.0 363.2	340.8 - 369.5	3,197	402.1	330.4	208.5 - 322.2	0,190	438.1	207.0	229.3 - 245
KES Sussex CH	2,743 6	227 3812	MT.0 - 375.8	2,907	\$10.9	302.0	208.8 - 325.2	5,650	510.0	341.8	212.2 - 261
Ot Kelt and Medway CN	3,701 4	21.0 381.0	203.5 - 284.4	3,816	404.0	340.7	229.2 - 352.2	T,530	468.2	381.3	352.9 - 369
KISS Street or Middle and s. C.N.	4.832 5	01.1 200.6	262.0 - 402.0	4.010	480.2	245.2	215.3 - 350.5	9.212	490.6	270.7	352.8 - 378
COLUMN OFFICE OF CH	7,730 5	21.2 424.0	616.0 - 636.1	T.880	514.6	271.4	352.T - 380.E	15,610	522.8	MILE	2015 - 401
GT ANGLECH	0.507 5	020 300 0	272.6 - 201.4	0.315	473.2	201.0	228.1 - 345.8	12,829	407.4	2015	352.0 - 365
OR FINAL CM	3.962 4	27.7 277.2	265.5 - 269.1	3.073	400.0	220.4	318.5 - 340.4	7.835	487.0	2012	345.2 - 361
Ingland	110,000	968 4978	405.8 - 410.2	110,340	and the	222	200.1 - 204.2	239,613	4769	200	2014 - 201
inth of Soctions CN	3.362 6	018 2002	235.6 - 403.1	3.450	534.5	2012	250.0 - 375.7	0.810	518.4	276.1	3MLT - 385
outs Each artificiations City	3.537 6	220 4214	617.0 - 665.8	3.710	519.7	207.2	276.2 - 400.2	T.229	530.8	601.7	200.0 - 410
West of Scotland CH		201 4800		8,802	519.6	383.4	273.0 - 388.2	12,542	522.7	419.5	419.0 - 425
todasi	12,749 (HB.1 400.1	424 474	19,560	601.5	279.3	373.0 - 300.0	26,800	100.0	au	200.0 - 400
orth Wates Ch	2.099 0	001 4812	611.6 - 670.9	2.010	514.0	2012	272.9 - 410.4	4.152	615.0	617	438.3 - 435
Sulfs West Mates CH		903 4963	208.7 - 422.0	2.426	545.4	201.0	251.1 - 382.7	4.545	530.1	201.0	279.0 - 402
Isah Eeri Wels CH		975.1 479.4		3,616	495.2	372.3	259.3 - 305.0	T,509	534.5	G2.E	412.0 - 433
Males	8,860 (HE4 4405	400-403	0,107	688.4	276.1	300.4 - 300.8	10,007	100.0	412.4	405.0 - 410
Softhern Instand	2.417	DAT 1881	279.1 - 496.4	2.807	ats	207.4	225.2 - 246.5	6.864	400.0	-	200.2 - 272





Networks above 99.8% control limit: NOS Yorkshire

Networks below 99.8% control limit:

Trends in 1 year survival: England 1985-2004



C00-C97 excl. C44: All malignant neoplasms (excl. non-melanoma skin cancer)

Years of diagnosis	Number in Cohort	Cumulative Deaths	% Crude Survival	% Relative Survival	95% Confidence Interval
1985-1989	414,345	221,027	46.7	49.3	49.1 - 49.5
1990-1994	445,012	219,778	50.6	53.6	53.4 - 53.7
1995-1999	468,127	206,001	56.0	58.9	58.7 - 59.0
2000-2004	504,166	196,766	61.0	64.1	63.9 - 64.2

Number in	Cumulative	% Crude	% Relative	95%
Cohort	Deaths	Survival	Survival	Confidence Interval
423,315	172,317	59.3	61.4	61.3 - 61.6
453,522	172,691	61.9	64.2	64.0 - 64.3
475,530	168,215	64.6	67.0	66.8 - 67.1
498,802	164,881	66.9	69.4	69.3 - 69.5

Females

Number in	Cumulative	% Crude	% Relative	95%
Cohort	Deaths	Survival	Survival	Confidence Interval
837,660	393,344	53.0	55.5	55.4 - 55.6
898,534	392,469	56.3	59.0	58.9 - 59.1
943,657	374,216	60.3	63.0	62.9 - 63.1
1,002,968	361,647	63.9	66.7	66.6 - 66.8

Persons

Estimated change per 5-yr cohort (%):	5.0	4.3 -	5.7		
P value:	0.001				
Notes on Trend					

Males

Estimated change per 5-yr cohort (%):	2.7	2.4 -	2.9
P value:	< 0.001		

Estimated change per 5-yr cohort (%):	3.8	3.5 -	4.1	
P value:	< 0.001			


Estimated 5.0% change per 5 year cohort gives an estimated increase of 1% per


Notes on Trend


Estimated 2.7% change per 5 year cohort gives an estimated increase of 0.53% per annum.

Notes on Trend

Estimated 3.8% change per 5 year cohort gives an estimated increase of 0.76% per annum.








Nothing 5 year contons

- - - - Dotted lines show 95% confidence limits

Oesophagus: Trends in 1yr survival








Oesophagus 2005 by Cancer Network








Lung Cancer Incidence by deprivation



national cancer intelligence network

Cancer incidence by deprivation quintile, England, 1995 - 2004








Major surgical resections England, 2004-2006

Major resection rates by age



Percentage of patients with a record of a major resection, by age and cancer site, patients diagnosed 2004-2006, followed up to 2007




Age group



Using information to improve quality & choice


Cancer Networks – Lung













Using information to improve quality & choice

Routes to Diagnosis	GP/OP referral	Two Week Wait	Emergency presentation	Other outpatient	Screen detected	Inpatient elective	ОСО	Unknown	Total	Number of patients
Acute leukaemia	17%	3%	61%	12%	0%	4%	0%	4%	100%	380
Bladder	22%	36%	18%	13%	0%	6%	1%	5%	100%	1,167
Brain & CNS	18%	2%	49%	20%	0%	5%	0%	5%	100%	740
Breast	8%	40%	5%	5%	28%	2%	0%	13%	100%	5,646
Cervix	21%	17%	12%	8%	23%	3%	1%	15%	100%	308
Chronic leukaemia	26%	6%	45%	13%	0%	4%	1%	4%	100%	629
Colorectal	19%	29%	24%	12%	0%	8%	0%	7%	100%	4,515
Kidney	22%	26%	23%	16%	0%	5%	0%	8%	100%	928
Larynx	35%	34%	8%	14%	0%	5%	0%	3%	100%	216
Lung	15%	26%	38%	10%	0%	4%	1%	7%	100%	3,893
Melanoma	23%	39%	4%	8%	0%	5%	0%	22%	100%	1,686
Multiple myeloma	20%	14%	44%	13%	0%	4%	1%	5%	100%	606
Non-Hodgkin's lymphoma	25%	22%	25%	13%	0%	6%	1%	9%	100%	1,349
Oesophagus	15%	32%	21%	14%	0%	13%	0%	4%	100%	912
Oral	32%	27%	5%	14%	0%	4%	1%	17%	100%	458
Ovary	20%	29%	28%	11%	0%	3%	1%	8%	100%	853
Pancreas	13%	20%	45%	10%	0%	5%	1%	7%	100%	917
Prostate	26%	28%	11%	11%	0%	7%	0%	16%	100%	4,865
Stomach	14%	24%	31%	13%	0%	11%	1%	6%	100%	801
tbc (other)	21%	18%	34%	12%	0%	4%	1%	9%	100%	4,323
Testis	14%	47%	9%	15%	0%	4%	0%	11%	100%	259
Uterus	28%	36%	8%	12%	0%	5%	0%	12%	100%	918
Total	19%	28%	22%	11%	5%	5%	1%	10%	100%	36,369



All cancer Routes to Diagnosis: by cancer type

All malignant registrations South West 2007 excluding C44 and multiples





Relative one year survival: by cancer type




Malignant registrations, South West 2007, excluding multiples and DCOs

	GP/OP refer	ral (+TWW)	Emerg	gency	Other	route	EUROCARE
Cancer type	Relative	95% Cls	Relative	95% Cls	Relative	95% Cls	Relative
	Survival	30 /0 CIS	Survival	90 /0 CIS	Survival	33 /0 CIS	Survival
Acute leukaemia	39.7	(28.1 - 51)	39.4	(32.9 - 45.8)	40.4	(29 - 51.5)	
Bladder	78.3	(74.6 - 81.5)	34.0	(27.3 - 40.8)	79.2	(73.2 - 84)	85.3
Brain & CNS	68.4	(60.1 - 75.4)	34.0	(29.1 - 38.9)	60.6	(53.6 - 66.8)	39.1
Breast	97.7	(96.8 - 98.4)	50.8	(44.4 - 56.9)	98.2	(97.5 - 98.8)	95
Colorectal	84.5	(82.7 - 86.2)	48.4	(45.2 - 51.5)	79.5	(76.9 - 81.9)	74.7
Kidney	81.1	(76.8 - 84.7)	24.0	(18.4 - 30)	72.4	(66.1 - 77.7)	74.7
Lung	39.8	(37.4 - 42.3)	8.9	7.6 - 10.3)	32.4	(29.1 - 35.7)	36.1
Multiple myeloma	83.6	(76.8 - 88.5)	53.1	(46.5 - 59.2)	73.0	(63.7 - 80.3)	70.5
Non-Hodgkin's lymphoma	86.6	(83.2 - 89.3)	43.7	(38.1 - 49.1)	80.9	(76 - 84.9)	73.1
Oesophagus	43.8	(38.9 - 48.6)	22.4	(16.7 - 28.7)	45.5	(39.5 - 51.4)	36.3
Other	81.1	(79.8 - 82.4)	27.2	(25.2 - 29.2)	77.8	(76.1 - 79.5)	
Ovary	83.4	(79.1 - 86.9)	38.8	(32.4 - 45.1)	72.1	(64.7 - 78.3)	70.7
Pancreas	21.0	(16.6 - 25.9)	6.0	(4.1 - 8.6)	22.3	(16.8 - 28.4)	19.2
Prostate	98.0	(97 - 98.7)	48.2	(43.6 - 52.7)	98.3	(96.9 - 99.1)	92.2
Stomach	49.1	(43.1 - 54.8)	17.7	(13.3 - 22.8)	47.6	(41 - 54)	44.1



30 day mortality data: Colo-rectal cancer surgery







NCIN data briefings 2010-11



- CNS Tumour developing a tumour registry
- Soft tissue sarcomas Incidence & Survival
- Cervical cancer incidence and screening coverage
- Pancreatic carcinoma in the young
- Geographic variation in primary liver & gall bladder cancers
- Oral cavity cancers
- Major surgical resections in England
- Routes to diagnosis
- Malignant pleural mesothelioma
- Bone sarcomas incidence and survival
- Breast cancer (x3): Deprivation; elderly; ethnicity
- Prostate cancer survival
- Skin cancer registration
- 30-day colo-rectal surgery mortality
- The effect of rurality on cancer incidence and mortality
- Where do patients with blood cancers die?
- Survival of Children, Teenagers and Young Adults with Cancer in England



e-Products (www.ncin.org.uk)




- Cancer e-Atlas
- UK Cancer Information Service (UKCIS)
- Cancer Commissioning Toolkit
- GP Practice profiles
- HES Microsites
- Various portals:
 - Inequalities portal (with National Cancer Equality Initiative)
 - Cancer mortality by PCT



National Cancer e-Atlas www.ncin.org.uk/eatlas








Cancer Commissioning Toolkit - dashboard







GP Practice profiles

NCIN national cancer intelligence network

- Significantly different from PCT median
- Not signficantly different than PCT median
- Significance testing not appropriate



131.1

23.9

29.9

23.9

29.9

Cancer indicators in Practice 6, ANON PCT (1)





Two-week referrals with suspected skin cancer (Rate per 10,000 population)

Number of emergency admissions with cancer (Rate per 10,000 population)

Number of emergency presentations (Rate per 10,000 population)

Number of managed presentations (Rate per 10,000 population)

Number of other presenations (Rate per 10,000 population)



Natio	nal Cancer Action Team					Lowest 26	ith Percentile	75th	Highest
Domai n	Indicator (Rate or Ratio)	Number	Rate or Ratio	Median Practic	Lowest Practic	Quartile ranges	of practice ra	ates/ratios in PCT	Highest Practic
	Practice Population (% of average practice in PCT)	12874	159.9	94.5	19.8		•	0	261.4
.e	Practice Population aged 65+ (% of population in this practice aged 65+)	1882	15%	14%	0%		C+3	10	26%
Demographic	Socio-economic deprivation quintile, 1= affluent (% of practice population income deprived)	3	14%	15%	5%		C		35%
Ę.	New cancer cases (Crude rate - new cases per 10,000 population)	52	383.8	421.6	190.9		0 •		557.1
ă	Cancer deaths (Crude rate - deaths per 10,000 population)	22	126.0	186.6	105.0	0	•		282.7
	Prevalant cancer cases (% of population with cancer)	156	1.2%	1.2%	0.1%	Til.			3.0%
2	Number aged 60-74 screened (breast) in last 30 months (3 year coverage, %)	427	74.0	66.4	34.3		• (95.0
screening	Number aged 60-74 screened (breast) within 6 months of invitation (Uptake, %)	222	77.0	70.2	35.9		• •		96.8
	Number aged 24-49 screened (cervix) in last 42 months (3.5 year coverage, %)	426	84.9	68.0	33.2	-	•	0	97.4
Cancer	Number aged 60-69 screened (bowel) in last 30 months (2.5 year coverage, %)	239	46.8	69.2	32.7	0	•		96.0
ű	Number aged 60-69 screened (bowel) within 6 months of invitation (Uptake, %)	458	68.8	66.6	33.4	100	C	1	97.4
# B W	Two-week wait referrals (Rate per 10,000 population)	218	169.3	181.4	0.0		• 0		403.9
Cancer Waiting Times	Two-week referrals with cancer (Conversion rate - % of all TWW referrals with cancer)	29	13%	9%	0%		•	0	24%
0 > -	Number of new Cancer Waiting Time cases (number per 10,000 population)	56	43.5	37.9	0.0		•>	1200	92.9
	In-patient or Day-case Colonoscopy procedures (Rate per 10,000 population)	5	15.5	17.4	9.0		•		23.7
	In-patient or Day-Case Flexi-sig procedures (Rate per 10,000 population)	7	22.4	16.1	8.5		•	0	24.0
8	In-patient or Day-case UGI endoscopy procedures (Rate per 10,000 population)	13	16.7	17.1	8.1		C	10	23.9
g	Two-week referrals with suspected breast cancer (Rate per 10,000 population)	47	36.5	38.4	0.0		• 0		88.0
Diagnostics	Two-week referrals with suspected lower GI cancer (Rate per 10,000 population)	45	35.0	31.0	0.0		• 0		76.5
88	Two-week referrals with suspected lung cancer (Rate per 10,000 population)	3	2.3	5.0	0.0		•		17.2

27

15

25.8

15.6

18.2

18.5

0.0

8.1

10.4

8.0

10.4

21.0

23.5

15.9

19.5

15.2

3
3
3
ું
ö
4
-
7
1
್ರ
ó
3

Detailed "Microsites"



C Back				
4 4 1 of 1 ▶ ▶	100% ▼	Find Next Select a format ▼	Export 🗗	

Major LGIT Surgical Procedures: Any Diagnosis Procedures by Network of Trust and Consultant (Provider Based Analysis)

HES Cancer Data Extract 9 (1997/08 - 2006/07)

TIES Calicer Data Extract 9 (1997/08 - 2000/07)												
		1997- 1998	1998- 1999	1999- 2000	2000- 2001	2001- 2002	2002- 2003	2003- 2004	2004- 2005	2005- 2006	2006- 2007	Grand Total
East Kent Hospitals NHS Trust		162	178	163	174	158	144	145	148	142	139	1,553
	Excision of Rectum	98	137	106	117	84	136	121	142	123	146	1,210
	Tout Total	260	315	269	291	242	280	266	290	265	285	2,763
Maidstone and Tunbridge Wells NHS Trust	⊞ Colectomy	83	101	100	98	89	99	96	79	107	111	963
	Excision of Rectum	59	99	71	77	63	72	72	72	72	86	743
	Trust Total	142	200	171	175	152	171	168	151	179	197	1,706
Medway NHS Foundation Trust	Colectomy	49	63	50	71	63	66	74	67	59	48	610
	Excision of Rectum	49	48	49	39	49	52	49	60	63	63	521
	Trust Total	98	111	99	110	112	118	123	127	122	111	1,131
Dartford and Gravesham NHS Trust	Colectomy	33	42	42	49	47	43	52	46	47	48	449
	Excision of Rectum	37	16	24	37	36	27	35	38	41	49	340
	Trust Total	70	58	66	86	83	70	87	84	88	97	789
Grand Total		570	684	605	662	589	639	644	652	654	690	6,389

..with detailed "drill through"



Back

Major LGIT Surgical Procedures: Any Diagnosis

Procedures by Network of Trust and Consultant (Provider Based Analysis)

HES Cancer Data Extract 9 (1997/08 - 2006/07)

			1997- 1998	1998- 1999	1999- 2000	2000- 2001	2001- 2002	2002- 2003	2003- 2004	2004- 2005	2005- 2006	2006- 2007	Grand Total
East Kent Hospitals NHS Trust	Colectomy		162	178	163	174	158	144	145	148	142	139	1,553
	Excision of Rectum		98	137	106	117	84	136	121	142	123	146	1,210
	Trust Total	200	260	315	269	291	242	280	266	290	265	285	2,763
Maidstone and Tunbridge Wells NHS Trust	□ Colectomy	C	37	28	37	30	34	32	40	33	57	50	378
		C.	10	23	15	23	22	19	14	11	20	22	179
		C1472	10	8	10	17	10	18	21	8	15	9	126
		Cl	12	13	13	7	4	7	5	3	2		66
		Cl 49°4	8	13	8	5	7	9	3	8	2		63
		C:	4	11	9	3	6	4	5	4	3	3	52
		CL		3	7	10	2	2	2		2		28
		6-3-3					3	7	4	8	3		25
		C4										21	21
		CS	2	2	1	3	1	1	2	4		1	17
		7									3	2	5
		c										1	1
		6										1	1
												1	1
	■ Excision of Rectum		59	99	71	77	63	72	72	72	72	86	743
	Trust Total		142	200	171	175	152	171	168	151	179	197	1,706
Medway NHS Foundation Trust	⊕ Colectomy		49	63	50	71	63	66	74	67	59	48	610
	Excision of Rectum		49	48	49	39	49	52	49	60	63	63	521
	Trust Total		98	111	99	110	112	118	123	127	122	111	1,131

Dataset development




- Cancer Services & Outcomes Dataset (COSD)
- Radiotherapy Dataset (RTDS)
- Systemic Anti-Cancer Therapy dataset (SACT)
- RCPath datasets
- Others (e.g. Radiology)



Cancer Outcomes and Services Dataset – Process overview



Institute



Using information to improve quality & choice

Research potential



- Analysis of Data Repository (∞)
 - Hospital 'footprint'
 - Primary care data
- Follow up of longer term outcomes of patients in clinical trials:
 - OP visits/primary care data
 - Recurrence
 - Late effects
 - Survival
- Planning of clinical trials
- Biosample annotation
- Development of PROMS.....





"Liberating Information, Improving Outcomes"

NCIN and **UKACR** Conference

15-17 June 2011, Hilton London Metropole

Register at: www.ncin.org.uk





Using information to improve quality & choice

www.ncin.org.uk

